Additionally, the impacts of knockdown and inhibitors on tumor burden in our work demonstrate a role of targeted therapy for glioma, which is in agreement with the previous reports aimed to alter activity of MELK/EZH2/NF-κB axis (48). This evidence concerns the gene NFKB1 and glioma.